Table 3.
Methodological quality of randomised controlled trials
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE)† | |
|---|---|---|---|---|---|
| Assumed risk (per 1000) | Corresponding risk (per 1000) | ||||
| Adefovir | Tenofovir | ||||
| HBV-DNA suppression | 425 | 1000(429 to 1000) | RR 2.59 (1.01 to 6.67) | 694(3 studies) | low⊕⊕▯▯ |
| HBV-HIV coinfected subgroup | 185 | 440(248 to 784) | RR 2.38 (1.34 to 4.24) | 137(2 studies) | moderate⊕⊕⊕▯ |
| ALT normalization | 634 | 729(609 to 869) | RR 1.15 (0.96 to 1.37) | 768(5 studies) | low⊕⊕▯▯ |
| lamivudine-resistance subgroup | 554 | 731(554 to 964) | RR 1.32 (1.00 to 1.74) | 132(2 studies) | low⊕⊕▯▯ |
| HBeAg seroconversion | 140 | 167(104 to 267) | RR 1.19 (0.74 to 1.91) | 387(3 studies) | low⊕⊕▯▯ |
| HBsAg loss | 0 | 0 | RR 5.74 (0.32 to 102.59) | 615(2 studies) | high⊕⊕⊕⊕ |
*The corresponding risk (and its 95% CI) is based on the assumed risk in the entecavir group and the relative effect of the lamivudine (and its 95% CI).
†High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.